Health & Fitness 
Health and Fitness
Health and Fitness 
Fri, February 13, 2009
Obagi Medical Products to Report Fourth Quarter and Full Year 2008 Financial Results and Host a Conference Call on March 5
LONG BEACH, Calif.--([ BUSINESS WIRE ])--Obagi Medical Products, Inc. (Nasdaq:OMPI), today announced fourth quarter and full year 2008 financial results will be released before the market open on Thursday, March 5, and will be followed by an investor conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).
Investors interested in participating in the live call can dial (800) 762-8779 from the U.S. International callers can dial (480) 248-5081. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, March 19, by dialing (800) 406-7325 from the U.S., or (303) 590-3030 for international callers and entering confirmation code 3972128.
There also will be a simultaneous webcast available on the Investor Relations section of the Company's web site at [ www.obagi.com ]. For those unable to participate during the live broadcast, the webcast will be archived for 30 days.
About Obagi Medical Products, Inc.
Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics™ technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm®, 1988; Obagi-C® Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi® Professional-C (a line of highly stable vitamin C serums), 2005; Obagi® Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm™ eye treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm® M.D. Systems for normal to dry skin, June 2007; Obagi ELASTIderm™ Décolletage System, January 2008; SoluCLENZ Rx Gel for acne treatment in the pharmacy channel in August 2008; and the Obagi® Rosaclear™ System for Rosacea in January 2009. Visit [ www.obagi.com ] for more information.